Effects of reverse transcriptase inhibitors on colon cancer
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10661507
This study is looking at how certain medications used for HIV might help slow down changes in colon cancer by examining tissue samples from patients before and after treatment, so we can better understand their effects on the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10661507 on ClinicalTrials.gov |
What this research studies
This research investigates how certain medications, known as nucleoside reverse transcriptase inhibitors (NRTIs), can impact the genetic changes in colon cancer. By analyzing RNA from cancerous tissues, the study aims to understand how these drugs can block harmful genetic alterations caused by repetitive RNA elements. The research involves preclinical models and a Phase II clinical trial where biopsies from patients are collected before and after treatment to assess the effects of NRTIs on cancer progression. The collaboration of multiple labs enhances the study's ability to analyze the role of these drugs in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who are undergoing treatment.
Not a fit: Patients with non-colorectal cancers or those not eligible for NRTI treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with colon cancer, potentially improving their outcomes.
How similar studies have performed: Previous research has shown promising results with NRTIs in cancer treatment, indicating potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TING, DAVID TSAI — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: TING, DAVID TSAI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent